Categories: News

WLFI Partners with AB to Deploy the USD1 Stablecoin on AB Chain

SINGAPORE, Nov. 13, 2025 /PRNewswire/ — World Liberty Financial (WLFI) and AB Chain announced a collaboration under which USD1 has been deployed on AB Chain. Leveraging AB Chain’s high-performance network, USD1 delivers a faster and more convenient stablecoin experience for users.

- Advertisement -

The partnership further enriches AB Chain’s DeFi and payments ecosystem, strengthening use cases across trading, lending, and liquidity.

- Advertisement -

Meanwhile, the decentralized wallet AB Wallet aims to be the most user-friendly wallet for USD1 with zero-fee transfers, near-instant settlement, and full compatibility with all chains where USD1 is available. Looking ahead, AB Wallet is exploring USD1 yield and other value-added services.

- Advertisement -

The launch of USD1 marks an important step forward in AB Chain’s stablecoin infrastructure.

- Advertisement -

Learn more:
WLFI: www.worldlibertyfinancial.com
WLFI official X (Twitter): https://x.com/worldlibertyfi
AB DAO: www.ab.org
AB DAO official X (Twitter): https://x.com/ABDAO_Global
AB Charity Foundation: www.abfdn.org

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/wlfi-partners-with-ab-to-deploy-the-usd1-stablecoin-on-ab-chain-302614449.html

- Advertisement -

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

1 hour ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

1 hour ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

1 hour ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

1 hour ago